| Gene Symbol | ACSL4 |
| Full Name | Acyl-CoA Synthetase Long Chain Family Member 4 |
| Chromosome | Xq22.3 |
| Protein Type | Synthetase |
| Target Class | Enzyme |
| Function | is an important component in the neurobiology of neurodegenerative diseases. |
| Mechanism of Action | Enzyme inhibition — blocking ACSL4 prevents incorporation of PUFAs into membrane phospholipids, reducing ferroptosis susceptibility |
| Primary Expression | various neural cell types: |
| Subcellular Localization | Endoplasmic reticulum, peroxisomes |
| Druggability | Low (0.41) |
| Clinical Stage | Phase III |
| Molecular Weight | ~79 kDa |
| Pathways | Autophagy, Cholesterol, Epigenetic, Ferroptosis, Inflammasome |
| UniProt ID | O60488 |
| Ensembl ID | ENSG00000068366 |
| GeneCards | ACSL4 |
| Human Protein Atlas | ACSL4 |
| Associated Diseases | ALS, Alzheimer's Disease, CANCER, Carcinoma, Fibrosis, Hepatocellular Carcinoma |
| Known Drugs/Compounds | ROSIGLITAZONE, CURCUMIN, Calycosin, curcumin, PIOGLITAZONE, valproic acid |
| Interactions | ALOX12, GPX4, MTOR, TNF, BAX, SCD1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | ACSL4-Driven Ferroptotic Priming in Disease-Associ 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferro ACSL4-Ferroptotic Priming in Stressed Oligodendroc (+1 more) |
| KG Connections | 760 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |